Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

AMRX Amneal Pharmaceuticals Holding Co

5,87

0,00 (0,00%)

22 Nov 2024 - Geschlossen

Verzögert um 15 Minuten

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

08/14/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Nikita Shah

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
Von Okt 2024 bis Nov 2024

Click Here for more Amneal Pharmaceuticals Charts.

Amneal Pharmaceuticals (NYSE:AMRX)
Historical Stock Chart
Von Nov 2023 bis Nov 2024

Click Here for more Amneal Pharmaceuticals Charts.

News Amneal Pharmaceuticals Holding Co

Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
Donnerstag 5 September 2024 (3 Monate vor) • Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Dienstag 20 August 2024 (3 Monate vor) • Business Wire

Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Dienstag 20 August 2024 (3 Monate vor) • Business Wire

Form 144 - Report of proposed sale of securities
Mittwoch 14 August 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Mittwoch 14 August 2024 (3 Monate vor) • Edgar (US Regulatory)

UBS Beats Earnings Forecasts, Intel Divests Arm Holdings, Flutter Surges 9% in Premarket Trading, and More
Mittwoch 14 August 2024 (3 Monate vor) • IH Market News

Amneal Reports Second Quarter 2024 Financial Results
Freitag 9 August 2024 (3 Monate vor) • Business Wire

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
Mittwoch 7 August 2024 (4 Monate vor) • Business Wire

Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
Montag 29 Juli 2024 (4 Monate vor) • Business Wire

Amneal to Report Second Quarter 2024 Results on August 9, 2024
Donnerstag 11 Juli 2024 (4 Monate vor) • Business Wire

Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Dienstag 9 Juli 2024 (4 Monate vor) • Business Wire

Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Montag 1 Juli 2024 (5 Monate vor) • Business Wire

Weitere Amneal Pharmaceuticals Holding Co News-Artikel

Restaurant Brands New Ze...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen